WATERTOWN, Mass. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter ended September 30, 2019 on Thursday,

WATERTOWN, Mass. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced today that the Company’s permanent and specific J-Code for YUTIQ®

WATERTOWN, Mass. , Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ ® (fluocinolone

WATERTOWN, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is

WATERTOWN, Mass. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ® (fluocinolone

– Company reports total revenue of $7.2 million – – Two commercial product launches in U.S. are underway for DEXYCU ® and YUTIQ ® with 43 sales reps actively targeting uveitis specialists, cataract surgeons and ambulatory surgical centers – – YUTIQ receives specific and permanent J Code, effective

WATERTOWN, Mass. , July 30, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of data supporting the Company's YUTIQ ®

WATERTOWN, Mass. , July 25, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has

WATERTOWN, Mass. , July 24, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its second quarter ended June 30, 2019 on Wednesday, August 7

WATERTOWN, Mass. , July 23, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that three abstracts supporting the Company's YUTIQ ® (fluocinolone

Ms. DiCicco is a Veteran Healthcare Executive with 30 Years of Financial and Corporate Development Experience WATERTOWN, Mass. , July 15, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing

WATERTOWN, Mass. , July 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) (“Eyepoint”), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has joined the broad-market Russell

WATERTOWN, Mass. , June 13, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported the grant of inducement awards to Scott Jones , EyePoint’s newly

- Scott Jones Appointed as Chief Commercial Officer - - Said Saim, Ph.D., Appointed as Chief Technology Officer - WATERTOWN, Mass. , June 10, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing

WATERTOWN, Mass. , May 15, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled

- YUTIQ™ and DEXYCU™ commercially launched in 1Q2019 – - YUTIQ recommended for specific J-code by Centers for Medicare & Medicaid Services - - Debt refinancing and equity public offering generated net proceeds of approximately $30.0 million - - Company optimistic that current cash balance and cash

  –  36-month data showed a uveitis eye flare recurrence rate of 56.3% in YUTIQ-treated eyes vs. 92.9% in sham eyes -              – Durability of 36-month data and safety support long-term efficacy of YUTIQ - WATERTOWN, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.

WATERTOWN, Mass. , April 23, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its first quarter ended March 31, 2019 on Wednesday, May 8 .

Two Presentations Highlighting YUTIQ™ to be Presented at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Data from Two Phase 3 Studies of DEXYCU ™ to be presented at the 2019 American Society of Cataract and Refractive Surgery (ASCRS) and American Society of

WATERTOWN, Mass. , April 02, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that members of the management team are scheduled to present at the